The Role of T-Cadherin (CDH13) in Treatment Options with Garcinol in Melanoma
Author:
Staebler Sebastian1ORCID, Hoechst Sebastian1, Thongmao Aranya1, Schneider Nadja1, Bosserhoff Anja-Katrin1ORCID, Kuphal Silke1ORCID
Affiliation:
1. Institute of Biochemistry, Friedrich Alexander University Erlangen-Nürnberg, Fahrstrasse 17, 91054 Erlangen, Germany
Abstract
Targeted therapies with chemotherapeutic agents and immunotherapy with checkpoint inhibitors are among the systemic therapies recommended in the guidelines for clinicians to treat melanoma. Although there have been constant improvements in the treatment of melanoma, resistance to the established therapies continues to occur. Therefore, the purpose of this study was to explore the function of garcinol with regards to specific cancer properties such as proliferation and apoptosis. Garcinol, a natural compound isolated from the plant also known as mangosteen (Garcinia mangostana), is a newly discovered option for cancer treatment. Numerous pharmaceutical substances are derived from plants. For example, the derivates of camptothecin, extracted from the bark of the Chinese tree of happiness (Camptotheca acuminate), or paclitaxel, extracted from the bark of the Western yew tree (Taxus brevifolia), are used as anti-cancer drugs. Here, we show that garcinol reduced proliferation and induced apoptosis in melanoma cell lines. In addition, we found that those cells that are positive for the expression of the cell–cell adhesion molecule T-cadherin (CDH13) respond more sensitively to treatment with garcinol. After knock-down experiments with an siRNA pool against T-cadherin, the sensitivity to garcinol decreased and proliferation and anti-apoptotic behavior of the cells was restored. We conclude that patients who are T-cadherin-positive could especially benefit from a therapy with garcinol.
Funder
German Research Association
Reference34 articles.
1. Molecular Pathways and Mechanisms of BRAF in Cancer Therapy;Poulikakos;Clin. Cancer Res.,2022 2. Pastwińska, J., Karaś, K., Karwaciak, I., and Ratajewski, M. (2022). Targeting EGFR in melanoma—The sea of possibilities to overcome drug resistance. Biochim. Biophys. Acta Rev. Cancer, 1877. 3. Chantree, P., Martviset, P., Thongsepee, N., Sangpairoj, K., and Sornchuer, P. (2023). Anti-Inflammatory Effect of Garcinol Extracted from Garcinia dulcis via Modulating NF-kappaB Signalling Pathway. Nutrients, 15. 4. Kopytko, P., Piotrowska, K., Janisiak, J., and Tarnowski, M. (2021). Garcinol—A Natural Histone Acetyltransferase Inhibitor and New Anti-Cancer Epigenetic Drug. Int. J. Mol. Sci., 22. 5. Aggarwal, V., Tuli, H.S., Kaur, J., Aggarwal, D., Parashar, G., Chaturvedi Parashar, N., Kulkarni, S., Kaur, G., Sak, K., and Kumar, M. (2020). Garcinol Exhibits Anti-Neoplastic Effects by Targeting Diverse Oncogenic Factors in Tumour Cells. Biomedicines, 8.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|